Exploring the potential of psychedelics, lower doses of psilocybin are shown to enhance communication across brain networks and promote neural plasticity. However, using these substances without guidance may lead to nonspecific rewiring, emphasizing the importance of directed therapy before and after treatment. Current clinical trials, including those for MDMA, are navigating the complexities of FDA approval while highlighting the need for structured therapeutic approaches.
